Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yingxia Li

Showing results (191-200 of 204) with videos related to

Pageof 21
Sort By:
Cell Death & Disease|August 25, 2023
N<sup>6</sup>-methyladenosine modification of REG1α facilitates colorectal cancer progression via β-catenin/MYC/LDHA axis mediated glycolytic reprogrammingMingxia Zhou, Jing He, Yingxia Li, et al.
IUBMB Life|June 5, 2024
Hederagenol improves multiple sclerosis by modulating Th17 cell differentiationDongsheng Guan, Yingxia Li, Xu Zhao, et al.
Communications Chemistry|September 9, 2024
Development of ketalized unsaturated saccharides as multifunctional cysteine-targeting covalent warheadsSanfeng Dong, Hui Huang, Jintian Li, et al.
European Journal of Medicinal Chemistry|December 25, 2025
Discovery of CZL-077 as a potent, selective, and orally active p300/CBP bromodomain inhibitor with improved in vivo antitumor efficacyZonglong Chen, Ying Zhang, Hui Shen, et al.
Journal of Medicinal Chemistry|October 2, 2024
Discovery of CZL-046 with an (<i>S</i>)-3-Fluoropyrrolidin-2-one Scaffold as a p300 Bromodomain Inhibitor for the Treatment of Multiple MyelomaZonglong Chen, Hong Yang, Yan Zhang, et al.
Frontiers in Medicine|February 5, 2024
COVID-19 vaccination willingness among people living with HIV in Shijiazhuang, China: a cross-sectional surveyXihong Zhang, Haoting Zhan, Lijing Wang, et al.
Journal of Medicinal Chemistry|May 18, 2026
Discovery of CZL-149: A Novel, Highly Potent, and Orally Bioavailable Dual Inhibitor Targeting BET and p300/CBP Bromodomains with Strong Antitumor EfficacyZonglong Chen, Qiongyu Shi, Yan Zhang, et al.
Midwifery|April 18, 2017
A randomised controlled trial in comparing maternal and neonatal outcomes between hands-and-knees delivery position and supine position in ChinaHongyu Zhang, Shurong Huang, Xiaolan Guo, et al.
Materials Today. Bio|November 11, 2025
EUK nanozyme-loaded PL&GA coacervate droplets attenuate ulcerative colitis through restoring gut homeostasis and restricting intestinal cell ferroptosisMingxia Zhou, Linping Lu, Xinyu Xu, et al.
Bioorganic & Medicinal Chemistry Letters|December 13, 2023
Design and synthesis of cantharidin derivative DCZ5418 as a TRIP13 inhibitor with anti-multiple myeloma activity in vitro and in vivoSanfeng Dong, Ke Hu, Yulong Shi, et al.
Pageof 21

Showing results (191-200 of 204) with videos related to

Sort By:
Pageof 21
Cell Death & Disease|August 25, 2023
N<sup>6</sup>-methyladenosine modification of REG1α facilitates colorectal cancer progression via β-catenin/MYC/LDHA axis mediated glycolytic reprogrammingMingxia Zhou, Jing He, Yingxia Li, et al.
IUBMB Life|June 5, 2024
Hederagenol improves multiple sclerosis by modulating Th17 cell differentiationDongsheng Guan, Yingxia Li, Xu Zhao, et al.
Communications Chemistry|September 9, 2024
Development of ketalized unsaturated saccharides as multifunctional cysteine-targeting covalent warheadsSanfeng Dong, Hui Huang, Jintian Li, et al.
European Journal of Medicinal Chemistry|December 25, 2025
Discovery of CZL-077 as a potent, selective, and orally active p300/CBP bromodomain inhibitor with improved in vivo antitumor efficacyZonglong Chen, Ying Zhang, Hui Shen, et al.
Journal of Medicinal Chemistry|October 2, 2024
Discovery of CZL-046 with an (<i>S</i>)-3-Fluoropyrrolidin-2-one Scaffold as a p300 Bromodomain Inhibitor for the Treatment of Multiple MyelomaZonglong Chen, Hong Yang, Yan Zhang, et al.
Frontiers in Medicine|February 5, 2024
COVID-19 vaccination willingness among people living with HIV in Shijiazhuang, China: a cross-sectional surveyXihong Zhang, Haoting Zhan, Lijing Wang, et al.
Journal of Medicinal Chemistry|May 18, 2026
Discovery of CZL-149: A Novel, Highly Potent, and Orally Bioavailable Dual Inhibitor Targeting BET and p300/CBP Bromodomains with Strong Antitumor EfficacyZonglong Chen, Qiongyu Shi, Yan Zhang, et al.
Midwifery|April 18, 2017
A randomised controlled trial in comparing maternal and neonatal outcomes between hands-and-knees delivery position and supine position in ChinaHongyu Zhang, Shurong Huang, Xiaolan Guo, et al.
Materials Today. Bio|November 11, 2025
EUK nanozyme-loaded PL&GA coacervate droplets attenuate ulcerative colitis through restoring gut homeostasis and restricting intestinal cell ferroptosisMingxia Zhou, Linping Lu, Xinyu Xu, et al.
Bioorganic & Medicinal Chemistry Letters|December 13, 2023
Design and synthesis of cantharidin derivative DCZ5418 as a TRIP13 inhibitor with anti-multiple myeloma activity in vitro and in vivoSanfeng Dong, Ke Hu, Yulong Shi, et al.
Pageof 21